11β-hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action

Journal of Endocrinology

Volumn 186, Issue 2, 2005, Pages 251-271

  Draper, Nicole ^a   Stewart, Paul M ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; 3ALPHA(OR 20BETA) HYDROXYSTEROID DEHYDROGENASE; CORTICOSTEROID; CORTISONE; GLUCOCORTICOID; HYDROCORTISONE; ISOENZYME;

APPARENT MINERALOCORTICOID EXCESS SYNDROME; AUTOCRINE EFFECT; CATALYSIS; CUSHING DISEASE; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME DEFICIENCY; GLAUCOMA; HORMONE ACTION; HUMAN; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; INSULIN RESISTANCE; NONHUMAN; OBESITY; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; ANIMAL; ANIMAL MODEL; ENZYMOLOGY; GENETICS; METABOLISM; MOUSE; MOUSE MUTANT;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 2; 11-BETA-HYDROXYSTEROID DEHYDROGENASES; ANIMALS; AUTOCRINE COMMUNICATION; CORTISONE; GLAUCOMA; HUMANS; HYDROCORTISONE; HYPERTENSION; INSULIN RESISTANCE; MICE; MICE, KNOCKOUT; MODELS, ANIMAL; OBESITY; OSTEOPOROSIS;

EID: 23844516967     PISSN: 00220795     EISSN: None     Source Type: Journal    
DOI: 10.1677/joe.1.06019     Document Type: Review

References (181)

1. Agarwal AK 2001 Transcriptional influence of two poly purine-pyrimidine tracts located in the HSD11B2 (11 beta-hydroxysteroid dehydrogenase type 2) gene. Endocrine Research 27 1-9.
2. Agarwal AK, Monder C, Eckstein B & White PC 1989 Cloning and expression of rat cDNA encoding corticosteroid 11β-dehydrogenase. Journal of Biological Chemistry 264 18939-18943.
3. Agarwal AK, Tusie-Luna MT, Monder C & White PC 1990 Expression of 11β-hydroxysteroid dehydrogenase using recombinant Vaccinia virus. Molecular Endocrinology 4 1827-1832.
4. Agarwal AK, Mune T, Monder C & White PC 1994 NAD+-dependent isoform of 11β-hydroxysteroid dehydrogenase. Cloning and characterization of cDNA from sheep kidney. Journal of Biological Chemistry 269 25959-25962.
5. Agarwal AK, Mune T, Monder C & White PC 1995a Mutations in putative glycosylation sites of rat 11β-hydroxysteroid dehydrogenase affect enzymatic activity. Biochimica et Biophysica Acta 1248 70-74.
6. Agarwal AK, Rogerson FM, Mune T & White PC 1995b Analysis of the human gene encoding the kidney isozyme of 11 beta-hydroxysteroid dehydrogenase. Journal of Steroid Biochemistry and Molecular Biology 55 473-479.
7. Agarwal AK, Giacchetti G, Lavery G, Nikkila H, Palermo M, Ricketts M, McTernan C, Bianchi G, Manunta P, Strazzullo P, Mantero F, White PC & Stewart PM 2000 CA-repeat polymorphism in intron 1 of HSD11B2: effects on gene expression and salt sensitivity. Hypertension 36 187-194.
8. Alberts P, Engblom L, Edling N, Forsgren M, Klingstrom G, Larsson C, Ronquist-Nii Y, Ohman B & Abrahmsen L 2002 Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetologia 45 1528-1532.
9. Albiston AL, Obeyesekere VR, Smith RE & Krozowski ZS 1994 Cloning and tissue distribution of the human 11β-hydroxysteroid dehydrogenase type 2 enzyme. Molecular and Cellular Endocrinology 105 R11-R17.
10. Amelung D, Hubener HJ, Rocka L & Meyerheim G 1953 Conversion of cortisone to compound F. Journal of Clinical Endocrinology and Metabolism 13 1125-1126.
11. Arriza JL, Weinberger C, Corelli G, Glaser TM, Handelin BL, Houseman DE & Evans RM 1987 Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with glucocorticoid receptor. Science 237 268-275.
12. Arriza JL, Simerly RB, Swanson LW & Evans RM 1988 The neuronal mineralocorticoid receptor as a mediator of glucocorticoid response. Neuron 1 887-900.
13. Axelrod LR 1953 The separation and identification of mixtures of C21 and C19 steroids by paper chromatography. Journal of Biological Chemistry 205 173-184.
14. Baggia S, Albrecht ED, Babischkin JS & Pepe GJ 1990 Interconversion of cortisol and cortisone in baboon trophoblast and decidua cells in culture. Endocrinology 127 1735-1741.
15. Barf T, Vallgarda J, Emond R, Haggstrom C, Kurz G, Nygren A, Larwood V, Mosialou E, Axelsson K, Olsson R, Engblom L, Edling N, Ronquist-Nii Y, Ohman B, Alberts P & Abrahmsen L 2002 Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 11 beta-hydroxysteroid dehydrogenase type 1. Journal of Medicinal Chemistry 45 3813-3815.
16. Beavan S, Horner A, Bord S, Ireland D & Compston J 2001 Colocalization of glucocorticoid and mineralocorticoid receptors in human bone. Journal of Bone and Mineral Research 16 1496-1504.
17. Berger J, Tanen M, Elbrecht A, Hermanowski-Vosatka A, Moller DE, Wright SD & Thieringer R 2001 Peroxisome proliferator-activated receptor-gamma ligands inhibit adipocyte 11 beta-hydroxysteroid dehydrogenase type 1 expression and activity. Journal of Biological Chemistry 276 12629-12635.
18. Bernal AL, Flint AP, Anderson AB & Turnbull AC 1980 11 Beta-hydroxysteroid dehydrogenase activity (E.C. 1.1.1.146) in human placenta and decidua. Journal of Steroid Biochemistry 13 1081-1087.
19. Biason-Lauber A, Suter SL, Shackleton CH & Zachmann M 2000 Apparent cortisone reductase deficiency: a rare cause of hyperandrogenemia and hypercortisolism. Hormone Research 53 260-266.
20. Bland R, Worker CA, Noble BS, Eyre LJ, Bujalska IJ, Sheppard MC, Stewart PM & Hewison M 1999 Characterization of 11 beta-hydroxysteroid dehydrogenase activity and corticosteroid receptor expression in human osteosarcoma cell lines. Journal of Endocrinology 161 455-464.
21. Blum A, Martin HJ & Maser E 2000a Human 11 beta-hydroxysteroid dehydrogenase 1/carbonyl reductase: recombinant expression in the yeast Pichia pastoris and Escherichia coli. Toxicology 144 113-120.
22. Blum A, Martin HJ & Maser E 2000b Human 11 beta-hydroxysteroid dehydrogenase type 1 is enzymatically active in its nonglycosylated form. Biochemical and Biophysical Research Communications 276 428-434.
23. Brand E, Kato N, Chatelain N, Krozowski ZS, Jeunemaitre X, Corvol P, Plouin PF, Cambien F, Pascoe L & Soubrier F 1998 Structural analysis and evaluation of the 11 beta-hydroxysteroid dehydrogenase type 2 (11 beta-HSD2) gene in human essential hypertension. Journal of Hypertension 16 1627-1633.
24. Brem AS, Bina RB, King T & Morris DJ 1995 Bidirectional activity of 11 beta-hydroxysteroid dehydrogenase in vascular smooth muscle cells. Steroids 60 406-410.
25. Brown RW, Chapman KE, Edwards CRW & Seckl JR 1993 Human placental 11β-hydroxysteroid dehydrogenase: evidence for and partial purification of a distinct NAD-dependent isoform. Endocrinology 132 2614-2621.
26. Brown RW, Chapman KE, Kotelevtsev Y, Yau JL, Lindsay RS, Brett L, Leckie C, Murad P, Lyons V, Mullins JJ, Edwards CR & Seckl JR 1996 Cloning and production of antisera to human placental 11 beta-hydroxysteroid dehydrogenase type 2. Biochemical Journal 313 1007-1017.
27. Bujalska IJ, Kumar S & Stewart PM 1997 Does central obesity reflect 'Cushing's disease of the omentum'? Lancet 349 1210-1213.
28. Bujalska IJ, Kumar S, Hewison M & Stewart PM 1999 Differentiation of adipose stromal cells: the roles of glucocorticoids and 11 beta-hydroxysteroid dehydrogenase. Endocrinology 140 3188-3196.
29. Burton PJ & Waddell BJ 1994 11β-Hydroxysteroid dehydrogenase in the rat placenta: developmental changes and the effects of altered glucocorticoid exposure. Journal of Endocrinology 143 505-513.
30. Burton KB, Keutmann EH, Waterhouse C & Schluer EA 1953 The conversion of cortisone acetate to other alphaketolic steroids. Journal of Clinical Endocrinology and Metabolism 13 48-63.
31. Bush IE 1969 11β-Hydroxysteroid dehydrogenase: contrast between studies in vivo and studies in vitro. Advances in Biosciences 3 23-39.
32. Bush IE, Hunter SA & Meigs RA 1968 Metabolism of 11-oxygenated steroids. Metabolism in vitro by preparations of liver. Biochemical Journal 107 239-258.
33. Canalis E 1996 Clinical review 83. Mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis. Journal of Clinical Endocrinology and Metabolism 81 3441-3447.
34. Canalis E & Delany AM 2002 Mechanisms of glucocorticoid action in bone. Annals of the New York Academy of Sciences 966 73-81.
35. Chen TL, Aronow L & Feldman D 1977 Glucocorticoid receptors and inhibition of bone cell growth in primary culture. Endocrinology 100 619-628.
36. Chin D, Shackleton C, Prasad VK, Kohn B, David R, Imperato-McGinley J, Cohen H, McMahon DJ & Oberfield SE 2000 Increased 5 alpha-reductase and normal 11 beta-hydroxysteroid dehydrogenase metabolism of C19 and C21 steroids in a young population with polycystic ovarian syndrome. Journal of Pediatric Endocrinology and Metabolism 13 253-259.
37. Condon J, Ricketts ML, Whorwood CB & Stewart PM 1997 Ontogeny and sexual dimorphic expression of mouse type 2 11β-hydroxysteroid dehydrogenase. Molecular and Cellular Endocrinology 127 121-128.
38. Cooper MS, Walker EA. Bland R, Fraser WD, Hewison M & Stewart PM 2000 Expression and functional consequences of 11 beta-hydroxysteroid dehydrogenase activity in human bone. Bone 27 375-381.
39. Cooper MS, Bujalska I, Rabbitt E, Walker EA, Bland R, Sheppard MC, Hewison M & Stewart PM 2001 Modulation of 11 beta-hydroxysteroid dehydrogenase isozymes by proinflammatory cytokines in osteoblasts: an autocrine switch from glucocorticoid inactivation to activation. Journal of Bone Mineral Research 16 1037-1044.
40. Cooper MS, Rabbitt EH, Goddard PE, Bartlett WA, Hewison M & Stewart PM 2002 Osteoblastic 11 beta-hydroxysteroid dehydrogenase type 1 activity increases with age and glucocorticoid exposure. Journal of Bone Mineral Research 17 979-986.
41. Cope CL & Black E 1958 The production rate of cortisol in man. Lancet 14 1020-1024.
42. Coulter CL, Smith RE, Stowasser M, Sasano H, Krozowski ZS & Gordon RD 1999 Expression of 11 beta-hydroxysteroid dehydrogenase type 2 (11 betaHSD-2) in the developing human adrenal gland and human adrenal cortical carcinoma and adenoma. Molecular and Cellular Endocrinology 154 71-77.
43. Cushing H 1932 The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). Bulletin of the Johns Hopkins Hospital 50 137-195.
44. Dave-Sharma S, Wilson RC, Harbison MD, Newfield R, Azar MR, Krozowski ZS, Funder JW, Shackleton CH, Bradlow HL, Wei JQ, Hertecant J, Moran A, Neiberger RE, Balfe JW, Fattah A, Daneman D, Akkurt HI, De Santis C & New MI 1998 Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess. Journal of Clinical Endocrinology and Metabolism 83 2244-2254.
45. Despres JP, Moorjani S, Ferland M, Tremblay A, Lupien PJ, Nadeau A, Pinault S, Theriault G & Bouchard C 1989 Adipose tissue distribution and plasma lipoprotein levels in obese women. Importance of intra-abdominal fat. Arteriosclerosis 9 203-210.
46. Edwards CRW, Stewart PM, Burt D, Brett L, McIntyre MA, Sutanto WS, DeKloet ER & Monder C 1988 Localisation of 11β-hydroxysteroid dehydrogenase-tissue specific protector of the mineralocorticoid receptor. Lancet ii (8618) 986-989.
47. Eyre LJ, Rabbitt EH, Bland R, Hughes SV, Cooper MS, Sheppard MC, Stewart PM & Hewison M 2001 Expression of 11 beta-hydroxysteroid dehydrogenase in rat osteoblastic cells: pre-receptor regulation of glucocorticoid responses in bone. Journal of Cellular Biochemistry 81 453-462.
48. Fassnacht M, Schlenz N, Schneider SB, Wudy SA, Allolio B & Arlt W 2003 Beyond adrenal and ovarian androgen generation - increased peripheral 5 alpha-reductase activity in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 88 2760-2766.
49. Ferrari P, Obeyesekere VR, Li K, Wilson RC, New MI, Funder JW & Krozowski ZS 1996 Point mutations abolish 11β-hydroxysteroid dehydrogenase type II activity in three families with the congenital syndrome of apparent mineralocorticoid excess. Molecular and Cellular Endocrinology 119 21-24.
50. Ferrari P, Sansonnens A, Dick B & Frey FJ 2001 In vivo 11 beta-HSD-2 activity: variability, salt-sensitivity, and effect of licorice. Hypertension 38 1330-1336.
51. Fujioka S, Matsuzawa Y, Tokunaga K & Tarui S 1987 Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism 36 54-59.
52. Hauner H, Schmid P & Pfeiffer EF 1987 Glucocorticoids and insulin promote the differentiation of human adipocyte precursor cells into fat cells. Journal of Clinical Endocrinology and Metabolism 64 832-835.
53. Hellman L, Nakada F, Zumoff B, Fukushima D, Bradlow HL & Gallagher TF 1971 Renal capture and oxidation of cortisol in man. Journal of Clinical Endocrinology and Metabolism 33 52-62.
54. Hermanowski-Vosatka A, Gerhold D, Mundt SS, Loving VA, Lu M, Chen Y, Elbrecht A, Wu M, Doebber T, Kelly L, Milot D, Guo Q, Wang PR, Ippolito M, Chao YS, Wright SD & Thieringer R 2000 PPARalpha agonists reduce 11 beta-hydroxysteroid dehydrogenase type 1 in the liver. Biochemical and Biophysical Research Communications 279 330-336.
55. Hirasawa G, Sasano H, Suzuki T, Takeyama J, Muramatu Y, Fukushima K, Hiwatashi N, Toyota T, Nagura H & Krozowski ZS 1999 11 Beta-hydroxysteroid dehydrogenase type 2 and mineralocorticoid receptor in human fetal development. Journal of Clinical Endocrinology and Metabolism 84 1453-1458.
56. Holmes MC, Kotelevtsev Y, Mullins JJ & Seckl JR 2001 Phenotypic analysis of mice bearing targeted deletions of 11 beta-hydroxysteroid dehydrogenases 1 and 2 genes. Molecular and Cellular Endocrinology 171 15-20.
57. Hundertmark S, Buhler H, Ragosch V, Dinkelborg L, Arabin B & Weitzel HK 1995 Correlation of surfactant phosphatidylcholine synthesis and 11β-hydroxysteroid dehydrogenase in fetal lung. Endocrinology 136 2573-2578.
58. Jamieson P, Chapman KE, Edwards CR & Seckl JR, 1995 11β-Hydroxysteroid dehydrogenase is an exclusive 11β-reductase in primary cultures of rat hepatocytes: effect of physiochemical and hormonal manipulations. Endocrinology 136 4754-4761.
59. Jamieson A, Wallace AM, Andrew R, Nunez BS, Walker BR, Fraser R, White PC & Connell JM 1999 Apparent cortisone reductase deficiency: a functional defect in 11 beta-hydroxysteroid dehydrogenase type 1. Journal of Clinical Endocrinology and Metabolism 84 3570-3574.
60. Jenkins JS 1966 The metabolism of cortisol by human extra-hepatic tissues. Journal of Endocrinology 34 51-56.
61. Kendall EC 1971 Arthritis. In Cortisone pp. 121-137. Charles Scriber's Sons: New York.
62. Kendall JW & Allen C 1968 Studies on the glucocorticoid feedback control of ACTH secretion. Endocrinology 82 397-405.
63. Kenouch S, Lombes M, Delahaye F, Eugene E, Bonvalet JP & Farman N 1994 Human skin as target for aldosterone: coexpression of mineralocorticoid receptors and 11 beta-hydroxysteroid dehydrogenase. Journal of Clinical Endocrinology and Metabolism 79 1334-1341.
64. Kimura K, Endou H, Sudo J & Sakai F 1979 Glucose dehydrogenase (hexose 6-phosphate dehydrogenase) and the microsomal electron transport system. Evidence supporting their possible functional relationship. Journal of Biochemistry (Tokyo) 85 319-326.
65. Kitanaka S, Katsumata N, Tanae A, Hibi I, Takeyama K, Fuse H, Kato S & Tanaka T 1997 A new compound heterozygous mutation in the 11β-hydroxysteroid dehydrogenase type 2 gene in a case of apparent mineralocorticoid excess. Journal of Clinical Endocrinology and Metabolism 82 4054-4058.
66. Klemcke HG, Sampath KR, Yang K, Vallet JL & Christenson RK 2003 11 Beta-hydroxysteroid dehydrogenase and glucocorticoid receptor messenger RNA expression in porcine placentae: effects of stage of gestation, breed, and uterine environment. Biology of Reproduction 69 1945-1950.
67. Kletzien RF, Harris PK & Foellmi LA 1994 Glucose-6-phosphate dehydrogenase: a 'housekeeping' enzyme subject to tissue-specific regulation by hormones, nutrients, and oxidant stress. FASEB Journal 8 174-181.
68. Korbonits M, Bujalska I, Shimojo M, Nobes J, Jordan S, Grossman AB & Stewart PM 2001 Expression of 11 beta-hydroxysteroid dehydrogenase isoenzymes in the human pituitary: induction of the type 2 enzyme in corticotropinomas and other pituitary tumors. Journal of Clinical Endocrinology and Metabolism 86 2728-2733.
69. Kotelevtsev Y, Holmes MC, Burchell A, Houston PM, Schmoll D, Jamieson P, Best R, Brown R, Edwards CR, Seckl JR & Mullins JJ 1997 11 Beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. PNAS 94 14924-14929.
70. Kotelevtsev Y, Brown RW, Fleming S, Kenyon C, Edwards CR, Seckl JR & Mullins JJ 1999 Hypertension in mice lacking 11 beta-hydroxysteroid dehydrogenase type 2. Journal of Clinical Investigation 103 683-689.
71. Krozowski Z & Funder JW 1983 Renal mineralocorticoid receptors and hippocampal corticosterone-binding species have identical intinsic steroid specificity. PNAS 80 6056-6060.
72. Krozowski ZS, Maguire JA, Stein-Oakley AN, Dowling J, Smith RE & Andrews RK 1995 Immunohistochemical localization of the 11β-hydroxysteroid dehydrogenase type II enzyme in human kidney and placenta. Journal of Clinical Endocrinology and Metabolism 80 2203-2209.
73. Laing I, Adams JE, Wood PJ, Taylor NF & Ray DW 2002 Cortisone reductase deficiency (11 beta-hydroxysteroid dehydrogenase type 1) deficiency presenting with features of late onset congenital adrenal hyperplasia. 21st Joint Meeting of the British Endocrine Societies, 8-11 April 2002.
74. Lakshmi V & Monder C 1988 Purification and characterization of the corticosteroid 11β-dehydrogenase component of the rat liver 11β-hydroxysteroid dehydrogenase complex. Endocrinology 123 2390-2398.
75. Lakshmi V, Nath N & Muneyyirci-Delale O 1993 Characterisation of 11β-hydroxysteroid dehydrogenase of human placenta: evidence for the existence of two species of 11β- hydroxysteroid dehydrogenase. Journal of Steroid Biochemistry and Molecular Biology 45 391-397.
76. Lavery GG, McTernan CL, Bain SC, Chowdhury TA, Hewison M & Stewart PM 2002 Association studies between the HSD11B2 gene (encoding human 11 beta-hydroxysteroid dehydrogenase type 2), type 1 diabetes mellitus and diabetic nephropathy. European Journal of Endocrinology 146 553-558.
77. Lavery GG, Ronconi V, Draper N, Rabbitt EA, Lyons V, Chapman KE, Walker EA, McTernan CL, Giacchetti G, Mantero F, Seckl JR, Edwards CRW, Conell JMC, Hewison M & Stewart PM 2003 Late onset 'apparent mineralocorticoid excess' due to novel compound heterozygous mutations in the HSD11B2 gene. Hypertension 42 123-129.
78. Leckie CM, Welberg LA & Seckl JR 1998 11 Beta-hydroxysteroid dehydrogenase is a predominant reductase in intact rat Leydig cells. Journal of Endocrinology 159 233-238.
79. Li A, Li KXZ, Marui S, Krozowski ZS, Batista MC, Whorwood CB, Arnhold IJP, Shackleton CHL, Mendonca BB & Stewart PM 1997 Apparent mineralocorticoid excess in a Brazilian kindred: hypertension in the heterozygote state. Journal of Hypertension 15 1397-1402.
80. Li A, Tedde R, Krozowski ZS, Pala A, Li KX, Shackleton CH, Mantero F, Palermo M & Stewart PM 1998 Molecular basis for hypertension in the 'type II variant' of apparent mineralocorticoid excess. American Journal of Human Genetics 63 370-379.
81. Lindsay RS, Wake DJ, Nair S, Bunt J, Livingstone DE, Permana PA, Tataranni PA & Walker BR 2003 Subcutaneous adipose 11 beta-hydroxysteroid dehydrogenase type 1 activity and messenger ribonucleic acid levels are associated with adiposity and insulinemia in Pima Indians and Caucasians. Journal of Clinical Endocrinology and Metabolism 88 2738-2744.
82. Lin-Su K, Zhou P, Arora N, Betensky BP, New MI & Wilson RC 2004 In vitro expression studies of a novel mutation delta299 in a patient affected with apparent mineralocorticoid excess. Journal of Clinical Endocrinology and Metabolism 89 2024-2027.
83. Lopez BA & Craft IL 1981 Corticosteroid metabolism in vitro by human placenta, fetal membranes and decidua in early and late gestation. Placenta 2 279-285.
84. Malunowicz EM, Romer TE, Urban M & Bossowski A 2003 11 Beta-hydroxysteroid dehydrogenase type 1 deficiency ('apparent cortisone reductase deficiency') in a 6-year-old boy. Hormone Research 59 205-210.
85. Maser E, Volker B & Friebertshauser J 2002 11 Beta-hydroxysteroid dehydrogenase type 1 from human liver: dimerization and enzyme cooperativity support its postulated role as glucocorticoid reductase. Biochemistry 41 2459-2465.
86. Maser E, Friebertshauser J & Volker B 2003 Purification, characterization and NNK carbonyl reductase activities of 11 beta-hydroxysteroid dehydrogenase type 1 from human liver: enzyme cooperativity and significance in the detoxification of a tobacco-derived carcinogen. Chemico-Biological Interactions 143-144 435-448.
87. Mason PJ, Stevens D, Diez A, Knight SW, Scopes DA & Vulliamy TJ 1999 Human hexose-6-phosphate dehydrogenase (glucose 1-dehydrogenase) encoded at 1p36: coding sequence and expression. Blood Cells, Molecules, and Diseases 25 30-37.
88. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR & Flier JS 2001 A transgenic model of visceral obesity and the metabolic syndrome. Science 294 2166-2170.
89. Milford DV, Shackleton CH & Stewart PM 1995 Mineralocorticoid hypertension and congenital deficiency of 11 beta-hydroxysteroid dehydrogenase in a family with the syndrome of'apparent' mineralocorticoid excess. Clinical Endocrinology 43 241-246.
90. Moghettii P, Spiazza GG, Tosi F, Solagna E, Zenari MI, Muggeo M & Castello R 2002 Cortisol secretion and metabolism in PCOS women. 84th Annual Meeting of the Endocrine Society, San Francisco, CA, USA.
91. Monder C & Lakshmi V 1989 Evidence for kinetically distinct forms of corticosteroid 11β-dehydrogenase in rat liver microsomes. Journal of Steroid Biochemistry 32 77-83.
92. Monder C & White PC 1993 11 beta-hydroxysteroid dehydrogenase. Vitamins and Hormones 47 187-271.
93. Monder C, Shackleton CHL, Bradlow HL, New MI, Stoner E, Iohan F & Lakshmi V 1986 The syndrome of apparent mineralocorticoid excess: its association with 11β-dehydrogenase and 5β-reductase deficiency and some consequences for corticosteroid metabolism. Journal of Clinical Endocrinology and Metabolism 63 550-557.
94. Monder C, Miroff Y, Marandici A & Hardy M 1994 11β-Hydroxsysteroid dehydrogenase alleviates glucocorticoid-mediated inhibition of steroidogenesis in rat Leydig cells. Endocrinology 134 1199-1204.
95. Moore CC, Mellon SH, Murai J, Siiteri PK & Miller WL 1993 Structure and function of the hepatic form of 11 beta-hydroxysteroid dehydrogenase in the squirrel monkey, an animal model of glucocorticoid resistance. Endocrinology 133 368-375.
96. Morineau G, Marc JM, Boudi A, Galons H, Gourmelen M, Corvol P, Pascoe L & Fiet J 1999 Genetic, biochemical, and clinical studies of patients with A328 V or R213C mutations in 11 betaHSD2 causing apparent mineralocorticoid excess. Hypertension 34 435-441.
97. Morton NM, Ramage L & Seckl JR 2004 Down-regulation of adipose 11 beta-hydroxysteroid dehydrogenase type 1 by high-fat feeding in mice: a potential adaptive mechanism counteracting metabolic disease. Endocrinology 145 2707-2712.
98. Moudgil A, Rodic G, Jordon SC & Kamil ES 2000 Nephrocalcinosis and renal cysts associated with apparent mineralocorticoid excess syndrome. Pediatric Nephrology 15 60-62.
99. Mune T & White PC 1996 Apparent mineralocorticoid excess; genotype is correlated with biochemical phenotype. Hypertension 27 1193-1199.
100. Mune T, Rogerson FM, Nikkilä H, Agarwal AK & White PC 1995 Human hypertension caused by mutations in the kidney isozyme of 11β-hydroxysteroid dehydrogenase. Nature Genetics 10 394-399.
101. Naray-Fejes-Toth A & Fejes-Toth G 1995 Expression cloning of the aldosterone target cell-specific 11 beta-hydroxysteroid dehydrogenase from rabbit collecting duct cells. Endocrinology 136 2579-2586.
102. Nikkila H, Tannin GM, New MI, Taylor NF, Kalaitzoglou G, Monder C & White PC 1993 Defects in the HSD11 gene encoding 11 beta-hydroxysteroid dehydrogenase are not found in patients with apparent mineralocorticoid excess or 11-oxoreductase deficiency. Journal of Clinical Endocrinology and Metabolism 77 687-691.
103. Nobel CS, Dunas F & Abrahmsen LB 2002 Purification of full-length recombinant human and rat type 1 11 beta-hydroxysteroid dehydrogenases with retained oxidoreductase activities. Protein Expression and Purification 26 349-356.
104. Nordenstrom A, Marcus C, Axelson M, Wedell A & Ritzen EM 1999 Failure of cortisone acetate treatment in congenital adrenal hyperplasia because of defective 11 beta-hydroxysteroid dehydrogenase reductase activity. Journal of Clinical Endocrinology and Metabolism 84 1210-1213.
105. Nunez BS, Rogerson FM, Mune T, Igarishi Y, Nakagawa Y, Phillipov G, Moudgil A, Travis LB, Palermo M, Shackleton C & White PC 1999 Mutants of 11 beta-hydroxysteroid dehydrogenase (11-HSD2) with partial activity: improved correlations between genotype and biochemical phenotype in apparent mineralocorticoid excess. Hypertension 34 638-642.
106. Obeyesekere VR, Trzeciak WH, Li KX & Krozowski ZS 1998 Serines at the active site of 11 beta-hydroxysteroid dehydrogenase type I determine the rate of catalysis. Biochemical and Biophysical Research Communications 250 469-473.
107. Odermatt A, Arnold P, Stauffer A, Frey BM & Frey FJ 1999 The N-terminal anchor sequences of 11 beta-hydroxysteroid dehydrogenases determine their orientation in the endoplasmic reticulum membrane. Journal of Biological Chemistry 274 28762-28770.
108. Odermatt A, Dick B, Arnold P, Zaehner T, Plueschke V, Deregibus MN, Repetto H, Frey BM, Frey FJ & Ferrari P 2001 A mutation in the cofactor-binding domain of 11 beta-hydroxysteroid dehydrogenase type 2 associated with mineralocorticoid hypertension. Journal of Clinical Endocrinology and Metabolism 86 1247-1252.
109. Osinski PA 1960 Steroid 11β-ol dehydrogenase in human placenta. Nature 187 777.
110. Ozols J 1995 Lumenal orientation and post-translational modifications of the liver microsomal 11 beta-hydroxysteroid dehydrogenase [published erratum appears in Journal of Biological Chemistry 1995 270 10360]. Journal of Biological Chemistry 270 2305-2312.
111. Palermo M, Shackleton CHL, Mantero F & Stewart PM 1996 Urinary free cortisone and the assessment of 11β-hydroxysteroid dehydrogenase activity in man. Clinical Endocrinology 45 605-611.
112. Palermo M, Cossu M & Shackleton CH 1998 Cure of apparent mineralocorticoid excess by kidney transplantation. New England Journal of Medicine 339 1787-1788.
113. Parks LL, Turney MK, Gaitan D & Kovacs WJ 1998 Expression of 11 beta-hydroxysteroid dehydrogenase type 2 in an ACTH-producing small cell lung cancer. Journal of Steroid Biochemistry and Molecular Biology 67 341-346.
114. Paulmyer-Lacroix O, Boullu S, Oliver C, Alessi MC & Grino M 2002 Expression of the mRNA coding for 11 beta-hydroxysteroid dehydrogenase type 1 in adipose tissue from obese patients: an in situ hybridization study. Journal of Clinical Endocrinology and Metabolism 87 2701-2705.
115. Pepe GJ, Burch MG & Albrecht ED 1999 Expression of the 11 beta-hydroxysteroid dehydrogenase types 1 and 2 proteins in human and baboon placental syncytiotrophoblast. Placenta 20 575-582.
116. Persson B, Krook M & Jörnvall H 1991 Characteristics of short-chain alcohol dehydrogenases and related enzymes. European Journal of Biochemistry 200 537-543.
117. Phillipou G & Higgins BA 1985 A new defect in the peripheral conversion of cortisone to cortisol. Journal of Steroid Biochemistry 22 435-436.
118. Phillipov G, Palermo M & Shackleton CH 1996 Apparent cortisone reductase deficiency: a unique form of hypercortisolism. Journal of Clinical Endocrinology and Metabolism 81 3855-3860.
119. Phillips DM, Lakshmi V & Monder C 1989 Corticosteroid 11β-dehydrogenase in rat testis. Endocrinology 125 209-216.
120. Pu X & Yang K 2000 Guinea pig 11 beta-hydroxysteroid dehydrogenase type 1: primary structure and catalytic properties. Steroids 65 148-156.
121. Quinkler M, Bappal B, Draper N, Atterbury AJ, Lavery GG, Walker EA, DeSilva V, Taylor NF, Hala S, Rajendra N & Stewart PM 2004 Molecular basis for the apparent mineralocorticoid excess syndrome in the Oman population. Molecular and Cellular Endocrinology 217 143-149.
122. Rabbitt EH, Lavery GG, Walker EA, Cooper MS, Stewart PM & Hewison M 2002 Prereceptor regulation of glucocorticoid action by 11 beta-hydroxysteroid dehydrogenase: a novel determinant of cell proliferation. FASEB Journal 16 36-44.
123. Rajan V, Chapman KE, Lyons V, Jamieson P, Mullins JJ, Edwards CRW & Seckl JR 1995 Cloning, sequencing and tissue distribution of mouse 11β-hydroxysteroid dehydrogenase-1 cDNA. Journal of Steroid Biochemistry and Molecular Biology 52 141-147.
124. Rajan V, Edwards CR & Seckl JR 1996 11 Beta-hydroxysteroid dehydrogenase in cultured hippocampal cells reactivates inert 11-dehydrocorticosterone, potentiating neurotoxicity. Journal of Neuroscience 16 65-70.
125. Rask E, Olsson T, Soderberg S, Andrew R, Livingstone DE, Johnson O & Walker BR 2001 Tissue-specific dysregulation of cortisol metabolism in human obesity. Journal of Clinical Endocrinology and Metabolism 86 1418-1421.
126. Rauz S, Walker EA, Shackleton CH, Hewison M, Murray PI & Stewart PM 2001 Expression and putative role of 11 beta-hydroxysteroid dehydrogenase isozymes within the human eye. Investigative Ophthalmology and Visual Science 42 2037-2042.
127. Ricketts ML, Verhaeg J, Bujalska I, Howie AJ, Rainey WE & Stewart PM 1998 Immunohistological localization of type 1 11β-hydroxysteroid dehydrogenase in human tissues. Journal of Clinical Endocrinology and Metabolism 83 1325-1335.
128. Riddle MC & McDaniel PA 1994 Renal 11 beta-hydroxysteroid dehydrogenase activity is enhanced by ramipril and captopril. Journal of Clinical Endocrinology and Metabolism 78 830-834.
129. Rodin A, Thakkar H, Taylor N & Clayton R 1994 Hyperandrogenism in polycystic ovary syndrome: evidence of dysregulation of 11β-hydroxysteroid dehydrogenase. New England Journal of Medicine 330 460-465.
130. Rogatsky I, Trowbridge JM & Garabedian MJ 1997 Glucocorticoid receptor-mediated cell cycle arrest is achieved through distinct cell-specific transcriptional regulatory mechanisms. Molecular Cell Biology 17 3181-3193.
131. Rogoff D, Smolenicka Z, Bergada I, Vallejo G, Barontini M, Heinrich JJ & Ferrari P 1998 The codon 213 of the 11 beta-hydroxysteroid dehydrogenase type 2 gene is a hot spot for mutations in apparent mineralocorticoid excess. Journal of Clinical Endocrinology and Metabolism 83 4391-4393.
132. Roland BL & Funder JW 1996 Localization of 11 beta-hydroxysteroid dehydrogenase type 2 in rat tissues: in situ studies. Endocrinology 137 1123-1128.
133. Sanchez I, Goya L, Vallerga AK & Firestone GL 1993 Glucocorticoids reversibly arrest rat hepatoma cell growth by inducing an early G1 block in cell cycle progression. Cell Growth and Differentiation 4 215-225.
134. Savage MW 1991 Increased metabolic clearance of cortisol in corticosteroid 11-reductase deficiency. Journal of Endocrinology 129S 219.
135. Scarpitta AM & Sinagra D 2000 Polycystic ovary syndrome: an endocrine and metabolic disease. Gynecological Endocrinology 14 392-395.
136. Shackleton CHL & Stewart PM 1990 The hypertension of apparent mineralocorticoid excess (AME) syndrome. In Endocrine Hypertension, pp 155-173. Eds EG Biglieri & JE Melby. New York: Raven Press Ltd.
137. Shackleton CHL, Rodriguez J, Arteaga E, Lopez JM & Winter JSD 1985 Congenital 11β-hydroxysteroid dehydrogenase deficiency associated with juvenile hypertension. Corticosteroid metabolite profiles of four patients and their families. Clinical Endocrinology 22 701-712.
138. Shafqat N, Elleby B, Svensson S, Shafqat J, Jornvall H, Abrahmsen L & Oppermann U 2003 Comparative enzymology of 11 beta-hydroxysteroid dehydrogenase type 1 from glucocorticoid resistant (guinea pig) versus sensitive (human) species. Journal of Biological Chemistry 278 2030-2035.
139. Shams M, Kilby MD, Somerset DA, Howie A, Gupta A, Wood PJ, Afnan M & Stewart PM 1998 11β-Hydroxysteroid dehydrogenase type 2 in human pregnancy and reduced expression in intrauterine growth restriction. Human Reproduction 13 799-804.
140. Smolenicka Z, Bach E, Schaer A, Liechti-Gallati S, Frey BM, Frey FJ & Ferrari P 1998 A new polymorphic restriction site in the human 11 beta-hydroxysteroid dehydrogenase type 2 gene. Journal of Clinical Endocrinology and Metabolism 83 1814-1817.
141. Soro A, Ingram MC, Tonolo G, Glorioso N & Fraser R 1995 Evidence of coexisting changes in 11β-hydroxysteroid dehydrogenase and 5β-reductase activity in patients with untreated essential hypertension. Hypertension 25 67-70.
142. Sprague RG, Power MH & Mason HL 1950 Physiological effects of cortisone and pituitary adrenocorticotropic hormone (ACTH) in man. Journal of the American Medical Association 144 1341-1347.
143. Srivastava LS, Werk EE Jr, Thrasher K, Sholiton LJ, Kozera R, Nolten W & Knowles HC Jr 1973 Plasma cortisone concentration as measured by radioimmunoassay. Journal of Clinical Endocrinology and Metabolism 36 937-943.
144. Stegeman JJ & Klotz AV 1979 A possible role for microsomal hexose-6-phosphate dehydrogenase in microsomal electron transport and mixed-function oxygenase activity. Biochemical and Biophysical Research Communications 87 410-415.
145. Stewart PM 1996 11β-Hydoxysteroid dehydrogenase: implications for clinical medicine. Clinical Endocrinology 44 493-499.
146. Stewart PM, Corrie JET, Shackleton CHL & Edwards CRW 1988 Syndrome of apparent mineralocorticoid excess: a defect in the cortisol-cortisone shuttle. Journal of Clinical Investigation 82 340-349.
147. Stewart PM, Shackleton CHL, Beastall GH & Edwards CRW 1990 5α-Reductase activity in polycystic ovary syndrome. Lancet 335 431-433.
148. Stewart PM, Murry BA & Mason JI 1994 Human kidney 11β-hydroxysteroid dehydrogenase is a high affinity nicotinamide adenine dinucleotide-dependent enzyme and differs from the cloned 'type I' isoform. Journal of Clinical Endocrinology and Metabolism 79 480-484.
149. Stewart PM, Whorwood CB & Mason JI 1995 Type 2 11 beta-hydroxysteroid dehydrogenase in foetal and adult life. Journal of Steroid Biochemistry and Molecular Biology 55 465-471.
150. Stewart PM, Krozowski ZS, Gupta A, Milford DV, Howie AJ, Sheppard MC & Whorwood CB 1996 Hypertension in the syndrome of apparent mineralocorticoid excess due to mutation of the 11β-hydroxysteroid dehydrogenase type 2 gene. Lancet 347 88-91.
151. Stewart PM, Boulton A, Kumar S, Clark PM & Shackleton CH 1999 Cortisol metabolism in human obesity: impaired cortisone→cortisol conversion in subjects with central adiposity. Journal of Clinical Endocrinology and Metabolism 84 1022-1027.
152. Stokes J, Noble J, Brett L, Phillips C, Seckl JR, O'Brien C & Andrew R 2000 Distribution of glucocorticoid and mineralocorticoid receptors and 11 beta-hydroxysteroid dehydrogenases in human and rat ocular tissues. Investigative Ophthalmology and Visual Science 41 1629-1638.
153. Sun K, Yang K & Challis JR 1997 Differential expression of 11β-hydroxysteroid dehydrogenase types 1 and 2 in human placenta and fetal membranes. Journal of Clinical Endocrinology and Metabolism 82 300-305.
154. Suzuki S, Suzuki T, Tsubochi H, Koike K, Tateno H, Krozowski ZS & Sasano H 2000 Expression of 11 beta-hydroxysteroid dehydrogenase type 2 and mineralocorticoid receptor in primary lung carcinomas. Anticancer Research 20 323-328.
155. Suzuki T, Sasano H, Kaneko C, Ogawa S, Darnel AD & Krozowski ZS 2001 Immunohistochemical distribution of 11 beta-hydroxysteroid dehydrogenase in human eye. Molecular and Cellular Endocrinology 173 121-125.
156. Tannin GM, Agarwal AK, Monder C, New MI & White PC 1991 The human gene for 11β-hydroxysteroid dehydrogenase. Structure, tissue distribution, and chromosomal localization. Journal of Biological Chemistry 266 16653-16658.
157. Taylor NF, Bartlett WA & Dawson DJ 1984 Cortisone reductase deficiency: evidence for a new inborn error in metabolism of adrenal steroids. Journal of Endocrinology 102S 89.
158. Taylor NF, Pollock A & Dornan TL 2003 Corticosteroid 11-reductase deficiency: steroid studies in a further family. Journal of Clinical Investigation 13 238.
159. Tetsuka M, Yamamoto S, Hayashida N, Hayashi KG, Hayashi M, Acosta TJ & Miyamoto A 2003 Expression of 11 beta-hydroxysteroid dehydrogenases in bovine follicle and corpus luteum. Journal of Endocrinology 177 445-452.
160. Thieringer R, Balkovec JM, Chen HY, Frazier E, Le Grand CB, Li Z, Metzger JM, Mundt SS, Nunes CN, Strowski M, Olson SH, Robertson N, Strack AM, Schaeffer JM, Zhang BB & Hermanowski-Vosatka A 2004 A novel non-steroidal inhibitor of 11 beta-hydroxysteroid dehydrogenase type 1 improves features of metabolic syndrome in murine disease models. 23rd Joint Meeting of the British Endocrine Societies with the European Federation of Endocrine Societies, Brighton, UK 22-24 March 2004.
161. Tomlinson JW & Stewart PM 2001 Cortisol metabolism and the role of 11 beta-hydroxysteroid dehydrogenase. Best Practise and Research. Clinical Endocrinology and Metabolism 15 61-78.
162. Tomlinson JW, Sinha B, Bujalska I, Hewison M & Stewart PM 2002 Expression of 11 beta-hydroxysteroid dehydrogenase type 1 in adipose tissue is not increased in human obesity. Journal of Clinical Endocrinology and Metabolism 87 5630-5635.
163. Tomlinson JW, Crabtree N, Clark PM, Holder G, Toogood AA, Shackleton CH & Stewart PM 2003 Low-dose growth hormone inhibits 11 beta-hydroxysteroid dehydrogenase type 1 but has no effect upon fat mass in patients with simple obesity. Journal of Clinical Endocrinology and Metabolism 88 2113-2118.
164. Tomlinson JW, Moore JS, Clark PM, Holder G, Shakespeare L & Stewart PM 2004 Weight loss increases 11 beta-hydroxysteroid dehydrogenase type 1 expression in human adipose tissue. Journal of Clinical Endocrinology and Metabolism 89 2711-2716.
165. Ugrasbul F, Wiens T, Rubinstein P, New MI & Wilson RC 1999 Prevalence of mild apparent mineralocorticoid excess in Mennonites. Journal of Clinical Endocrinology and Metabolism 84 4735-4738.
166. Ulick S, Levine LS, Gunczler P, Zanconato G, Ramirex LC, Rauh W, Rosler A, Bradlow JL & New MI 1979 A syndrome of apparent mineralocorticoid excess associated with defects in the peripheral metabolism of cortisol. Journal of Clinical Endocrinology and Metabolism 49 757-764.
167. Valsamakis G, Anwar A, Tomlinson JW, Shackleton CH, McTernan PG, Chetty R, Wood PJ, Banerjee AK, Holder G, Barnett AH, Stewart PM & Kumar S 2004 11 Beta-hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism 89 4755-4761.
168. Walker BR, Stewart PM, Shackleton CHL, Padfield PL & Edwards CRW 1993 Deficient inactivation of cortisol by 11β-hydroxysteroid dehydrogenase in essential hypertension. Clinical Endocrinology 39 221-227.
169. Walker EA, Clark AM, Hewison M, Ride JP & Stewart PM 2001 Functional expression, characterization, and purification of the catalytic domain of human 11 beta-hydroxysteroid dehydrogenase type 1. Journal of Biological Chemistry 276 21343-21350.
170. White PC, Obeid J, Agarwal AK, Tannin GM & Nikkilä H 1994 Genetic analysis of 11β-hydroxysteroid dehydrogenase. Steroids 59 111-115.
171. White PC, Mune T & Agarwal AK 1997 11β-Hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocrine Reviews 18 135-156.
172. Whitworth JA, Stewart PM, Burt D, Atherden SM & Edwards CR 1989 The kidney is the major site of cortisone production in man. Clinical Endocrinology 31 355-361.
173. Whorwood CB & Stewart PM 1996 Human hypertension caused by mutations in the 11 beta-hydroxysteroid dehydrogenase gene: a molecular analysis of apparent mineralocorticoid excess. Journal of Hypertension (Supplement) 14 S19-S24.
174. Whorwood CB, Ricketts ML & Stewart PM 1994 Epithelial cell localization of type 2 11 beta-hydroxysteroid dehydrogenase in rat and human colon. Endocrinology 135 2533-2541.
175. Whorwood CB, Mason JI, Ricketts ML, Howie AJ & Stewart PM 1995 Detection of human 11 beta-hydroxysteroid dehydrogenase isoforms using reverse-transcriptase-polymerase chain reaction and localization of the type 2 isoform to renal collecting ducts. Molecular and Cellular Endocrinology 110 R7-R12.
176. Wilson RC, Harbison MD, Krozowski ZS, Funder JW, Shackleton CHL, Hanauske-Abel HM, Wei JQ, Hertecant J, Moran A, Neiberger RE, Balfe JW, Fattah A, Daneman D, Licholai T & New MI 1995a Several homozygous mutations in the gene for 11β-hydroxysteroid dehydrogenase type 2 in patients with apparent mineralocorticoid excess. Journal of Clinical Endocrinology and Metabolism 80 3145-3150.
177. Wilson RC, Krozowski ZS, Li K, Obeyesekere VR, Razzaghy-Azar M, Harbison MD, Wei JQ, Shackleton CHL, Funder JW & New MI 1995b A mutation in the HSD11B2 gene in a family with apparent mineralocorticoid excess. Journal of Clinical Endocrinology and Metabolism 80 2263-2266.
178. Wilson RC, Dave-Sharma S, Wei JQ, Obeyesekere VR, Li K, Ferrari P, Krozowski ZS, Shackleton CH, Bradlow L, Wiens T & New MI 1998 A genetic defect resulting in mild low-renin hypertension. PNAS 95 10200-10205.
179. Yang K, Smith CL, Dales D, Hammond GL & Challis JR 1992 Cloning of an ovine 11 beta-hydroxysteroid dehydrogenase complementary deoxyribonucleic acid: tissue and temporal distribution of its messenger ribonucleic acid during fetal and neonatal development. Endocrinology 131 2120-2126.
180. Yau JL, Olsson T, Morris RG, Meaney MJ & Seckl JR 1995 Glucocorticoids, hippocampal corticosteroid receptor gene expression and antidepressant treatment: relationship with spatial learning in young and aged rats. Neuroscience 66 571-581.
181. Zhou MY, Gomez-Sanchez EP, Cox DL, Cosby D & Gomez-Sanchez CE 1995 Cloning, expression, and tissue distribution of the rat nicotinamide adenine dinucleotide-dependent 11 beta-hydroxysteroid dehydrogenase. Endocrinology 136 3729-3734.